The pre-clinical data is very strong so it should be smooth sailing through phase one and hopefully phase two trials. They are eligible for a fast tracked approval process through the TGA so after phase one this will come in handy. There will be big money to be made in this stock as the company progresses through these goals but the register has to be tight to withstand the next year after the inevitable short term skyrocket. A long term hold is something Alto can easily command from their clients, they have made people a lot of money over the years.
